People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Biotechnology, Pharma, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| CytomX Therapeutics, Inc. | — | Biotechnology | Series C | $143.0M | $392.9M | 2010 |
| Star Therapeutics LLC | — | Pharma | Series D+ | $125.0M | $936.1M | 2025 |
| Latigo Biotherapeutics, Inc. | — | Biotechnology | Series C | $50.0M | $357.9M | 2025 |
| CytomX Therapeutics, LLC | — | Other | Seed | $13.4M | $27.9M | 2009 |
| biOasis Technologies Inc. | — | Biotechnology | Seed | $3.6M | $74.9M | 2018 |
Nancy Stagliano at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Nancy Stagliano on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Beth Seidenberg | 2 | 15 |
| Michael E. Pfau | 2 | 6 |
| Alan Heeger | 2 | 5 |
| Gary Wilcox | 2 | 4 |
| Carl Gordon | 1 | 24 |
| Matthew Young | 1 | 7 |
| Michael Pfau | 1 | 7 |
| Jason Hafler | 1 | 6 |
| Maha Katabi | 1 | 6 |
| Elaine Jones | 1 | 6 |
| Matthew Fust | 1 | 4 |
| Kevin Raidy | 1 | 4 |
| David M. Wurzer | 1 | 4 |
| Jim Tananbaum | 1 | 4 |
| Sean McCarthy | 1 | 3 |
| Mark Day | 1 | 3 |
| Frederick W Gluck | 1 | 3 |
| Elaine V. Jones | 1 | 3 |
| Scott Robertson | 1 | 3 |
| Deborah Palestrant | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.